Drug
Satoreotide Tetraxetan
Satoreotide Tetraxetan: highest development phase Phase 1/2, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Satoreotide tetraxetan NCT02592707 | Phase 1/2 | Neuroendocrine Tumors |
Latest
No recent events.
Follow Satoreotide Tetraxetan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.